CRACD

Across TCGA pan-cancer cohorts, CRACD mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CRACD data layer compared with 20 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CRACD mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CRACD expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, COAD, and LSCC are the cancer types where CRACD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	III,IV	0.737	0.260	.001	27	view →
COAD	DFS	Median	All	0.944	1.000	.042	12	view →
LSCC	DFS	Median	III,IV	0.437	0.811	.018	4	view →
CCRCC	DFS	Quartile	All	0.417	1.000	.013	2	view →
LUAD	OS	Median	II,III,IV	0.487	0.885	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CRACD–PDAC (OS)

Open the PDAC breakdown →